Preview

Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева

Расширенный поиск

Депрессия и рак: основные направления международных исследований

https://doi.org/10.31363/2313-7053-2020-2-16-25

Полный текст:

Аннотация

В обзорной статье раскрываются проблемы распространенности, диагностики, этиопатогенеза, последствий и психосоциального лечения депрессии у пациентов онкологического профиля согласно данным зарубежной литературы. Показано, что проявления эмоционального дистресса у онкологических пациентов значительно выше, тогда как распространенность большого депрессивного расстройства сравнима с показателями общей популяции. Депрессия может развиваться как реакция на постановку диагноза рака, посредством активизации нейроиммуноэндокринных механизмов реагирования на стресс, и может быть следствием биологических изменений, сопровождающих опухолевый процесс и его лечение. На современном этапе развития психосоциального лечения данного контингента больных все чаще разрабатываются и применяются программы доступной комплексной помощи пациентам, состоящие из нескольких модулей и проводимые непрофессионалами в области психического здоровья

Об авторе

А. Н. Блинков
Российская академия народного хозяйства и государственной службы при Президенте РФ
Россия
Блинков Александр Николаевич—кандидат психологических наук, доцент


Список литературы

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность)—М.: МНИОИим. П.А. Герцена—филиал ФГБУ «НМИЦ радиологии» МинздраваРоссии, 2018.—250 с.

2. Грушина Т.И., Ткаченко Г.А. Психологический дистресс у больных раком молочной железы после различных видов противоопухолевого лечения. Опухоли женской репродуктивной системы. 2016; 12(1):56-62.

3. Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. А.М. Беляев, В.А. Чулкова, Т.Ю. Семиглазова, М.В. Рогачев.—СПб: Любавич, 2017:352 с.

4. Allenby A., Matthews J., Beresford J., McLachlan S.A. The application of computer touch-screen technology in screening for psychosocial distress in an ambulatory oncology setting. Eur. J. Cancer Care. 2002; 11(4):245–253.

5. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing. 2013. doi:10.1176/appi.books.9780890425596.744053.

6. Andersen B.L., Farrar W.B., Golden-Kreutz D. et al. Distress reduction from a psychological inter- vention contributes to improved health for cancer patients. Brain, Behavior, and Immunity. 2007; 21(7):953–961. doi: 10.1016/j.bbi.2007.03.005.

7. Antoni M.H. Psychosocial intervention effects on adaptation, disease course and biobehavioral pro- cesses in cancer. Brain, Behavior, and Immunity. 2013; 30:88-98. doi: 10.1016/j.bbi.2012.05.009.

8. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6):394– 424. doi: 10.3322/caac.21492.

9. Caruso R., GiuliaNanni M., Riba M.B. et al.Depressive spectrum disorders in cancer: diagnostic issues and intervention. A critical review. Curr. Psychiatry Rep. 2017; 19(6):33. doi: 10.1007/s11920-017-0785-7.

10. Colleoni M., Mandala M., Peruzzotti G. et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000; 356(9238):1326–1327. doi: 10.1016/S0140-6736(00)02821-X.

11. Compen F.R., Adang E.M.M., Bisseling E.M. et al. Exploring associations between psychiatric disorder, psychological distress, and health care utilization in cancer patients. Psychooncology. 2018; 27(3):871– 878. doi: 10.1002/pon.4591.

12. Curry C., Cossich T., Matthews J.P. et al. Uptake of psychosocial referrals in an outpatient cancer setting: improving service accessibility via the referral process. Support Care Cancer. 2002; 10:549–555. doi: 10.1007/s00520-002-0371-2.

13. Danese A., Lewis J.S. Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma? Neuropsychopharmacology. 2017; 42(1):99–114. doi: 10.1038/npp.2016.198.

14. Dauchy S., Dolbeault S., Reichc M. Depression in cancer patients. EJC Suppl. 2013; 11(2):205–215. doi: 10.1016/j.ejcsup.2013.07.006.

15. de Figueiredo J.M. Depression and demoralization: phenomenologic differences and research perspectives. Compr. Psychiatry. 1993; 34(5):308–311. doi: 10.1016/0010-440x(93)90016-w.

16. de la Torre-Luque A., Gambara H., López E., Cruzado J.A. Psychological treatments to improve quality of life in cancer contexts: A meta-analysis. Int. J. Clin. Health Psychol. 2016; 16(2):211–219. doi: 10.1016/j.ijchp.2015.07.005

17. de Souza B.F., Pires F.H., Dewulf Nde L. et al. Pa- tients on chemotherapy: depression and adherence to treatment. Rev. Esc. Enferm. USP. 2013; 47(1):61– 68. doi: 10.1590/s0080-62342013000100008.

18. DiMatteo M.R., Lepper H.S., Croghan T.W. De- pression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. of Internal. Med. 2000; 160:2101–2107. doi: 10.1001/archinte.160.14.2101.

19. Donnelly J.M., Kornblith A.B., Fleishman S. et al. A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. Psychooncology. 2000; 9(1):44–56.

20. Ell K., Xie B., Quon B. et al. Randomized con- trolled trial of collaborative care management of depression among low-income patients with can- cer. J. Clin. Oncol. 2008; 26(27):4488–4496. doi: 10.1200/JCO.2008.16.6371.

21. Fawzy I.F., Fawzy N.W., Hyun C.S. et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry. 1993; 50:681–689. doi: 10.1001/archpsyc.1993.01820210015002.

22. Fawzy, F.I., Fawzy, N.W., Canada, A.L. Psychoeducational intervention programs for patients with cancer. In A. Baum & B. L. Andersen (Eds.), Psychosocial interventions for cancer. Washington, DC, US: American Psychological Association. 2001; 235–267.

23. Fogel J., Eaton W.W., Ford D.E. Minor depression as a predictor of the first onset of major depressive disorder over a 15-year follow-up. Acta Psychiatr. Scand. 2006; 113(1):36-43. doi: 10.1111/j.1600-0447.2005.00654.x.

24. Garssen B., Goodkin K. On the role of immunological factors as mediators between psychological factors and cancer progression. Psychiatry Res. 1999; 85:51–61. doi: 10.1016/s0165-1781(99)00008-6.

25. Gathright E.C., Goldstein C.M., Josephson R.A., Hughes J.W. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J. Psychosom. Res. 2017; 94:82–89. doi: 10.1016/j.jpsychores.2017.01.010.

26. Gilbody S., Bower P., Fletcher J. et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch. Intern. Med. 2006; 166(21):2314–2321. doi: 10.1001/archinte.166.21.2314

27. Gilman S.E., Sucha E., Kingsbury M. et al. Depression and mortality in a longitudinal study: 1952-2011. CMAJ. 2017; 189(42):1304–1310. doi: 10.1503/cmaj.170125.

28. Greenberg D.B. Barriers to the treatment of depression in cancer patients. J. Natl. Cancer Inst. Monogr. 2004; 32:127–135. doi: 10.1093/jncimonographs/lgh019.

29. Gunnar M., Quevedo K. The neurobiology of stress and development. Annu. Rev. Psychol. 2007; 58:145– 173. doi: 10.1146/annurev.psych.58.110405.085605.

30. Hass H.S., Schauenstein K. Immunity, hormones, and the brain. Allergy. 2001; 56:470–477. doi: 10.1034/j.1398-9995.2001.056006470.x.

31. Holmstrand C., Engström G., Träskman-Bendz L. Disentangling dysthymia from major depressive dis- order in suicide attempters’ suicidality, comorbid- ity and symptomatology. Nord. J. Psychiatry. 2008; 62(1):25–31. doi: 10.1080/08039480801960164.

32. Hopko D.R., Armento M.E., Robertson S.M. et al. Brief behavioral activation and problem-solv- ing therapy for depressed breast cancer patients: randomized trial. J. Consult. Clin. Psychol. 2011; 79(6):834–49. doi: 10.1037/a0025450.

33. Jacobsen P.B., Wagner L.I. A new quality standard: The integration of psychosocial care into routine cancer care. J. Clin. Oncol. 2012; 30:1154–1159. doi: 10.1200/JCO.2011.39.5046.

34. Kalat J.W. Biological Psychology (13th ed.). Cen- gage Learning US, 2019:624p.

35. Kang D.H., Park N.J., McArdle T. Cancer-Specific Stress and Mood Disturbance: Implications for Symptom Perception, Quality of Life, and Immune Response in Women Shortly after Diagnosis of Breast Cancer. ISRN Nurs. 2012: 608039. doi: 10.5402/2012/608039.

36. Katon W., Von Korff M., Lin E. et al. Stepped Collaborative Care for Primary Care Patients with Persistent Symptoms of Depression: a randomized trial. Arch. Gen. Psychiatry. 1999; 56(12):1109– 1115. doi: 10.1001/archpsyc.56.12.1109.

37. Kiecolt-Glaser J.K., Robles T.F., Heffner K.L. et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann. Oncol. 2002; 13:165–169. doi: 10.1093/annonc/mdf655.

38. Kim Y.K., Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatr. 2003; 15:148–155. doi: 10.1034/j.1601-5215.2003.00026.x.

39. Kohn R., Saxena S., Levav I., Saraceno B. The treatment gap in mental health care. B. World Health Organ. 2004; 82:858–866. doi: /S0042-96862004001100011.

40. Krebber A.M., Buffart L.M., Kleijn G. et al. Prevalence of depression in cancer patients: a metaanalysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2):121–130. doi: 10.1002/pon.3409.

41. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry. 2000; 157:683–694. doi: 10.1176/appi.ajp.157.5.683.

42. Lawrence D., Holman C.D., Jablensky A.V. et al. Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr. Scand. 2000; 101(5):382–388. doi: 10.1034/j.1600-0447.2000.101005382.x

43. Lee Y.H., Chiou P.Y., Chang P.H., Hayter M. A systematic review of the effectiveness of problemsolving approaches towards symptom management in cancer care. J. Clin. Nurs. 2011; 20(1-2):73–85. doi: 10.1111/j.1365-2702.2010.03401.x.

44. Levav I. The treatment gap of depression in persons with cancer. Asian Pac. J. Cancer P. 2010; 11:117–119.

45. Lewis G., Pelosi A.J., Araya R. et al. Measuring psychiatric disorders in the community: a stan- dardised assessment for use by lay interviewers. Psychol. Med. 1992; 22:465–486. doi: 10.1017/s0033291700030415.

46. Li M., Fitzgerald P., Rodin G. Evidence-based treatment of depression in patients with cancer. J. Clin. Oncol. 2012; 30(11):1187–1196. doi: 10.1200/JCO.2011.39.7372.

47. Liossi C., White P. Efficacy of clinical hypnosis in the enhancement of quality of life of terminally ill cancer patients. Contempor. Hypnosis. 2001; 18(3):145–160. doi: 10.1002/ch.228.

48. Maj M. When does depression become a mental disorder? Br. J. Psychiatry. 2011; 199(2):85–86. doi: 10.1192/bjp.bp.110.089094.

49. Markkula N., Marola N., Nieminen T. et al. Pre- dictors of new-onset depressive disorders—Results from the longitudinal Finnish Health 2011 Study. J. Affect. Disord. 2017; 208:255–264. doi: 10.1016/j.jad.2016.08.051.

50. Martínez M., Arantzamendi M., Belar A. et al. ‘Dignity therapy’, a promising intervention in palliative care: A comprehensive systematic literature review. Palliat. Med. 2017; 31(6):492–509. doi: 10.1177/0269216316665562.

51. Massie M.J. Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr. 2004; 32:57–71. doi: 10.1093/jncimonographs/lgh014.

52. Mausbach B.T., Irwin S.A. Depression and healthcare service utilization in patients with cancer. Psychooncology. 2017; 26(8):1133–1139. doi: 10.1002/pon.4133.

53. Misono S., Weiss N.S., Fann J.R. et al. Incidence of suicide in persons with cancer. J. Clin. Oncol. 2008; 26:4705–4707. doi: 10.1200/JCO.2007.13.8941.

54. Mitchell A.J., Chan M., Bhatti H. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011; 12:160–174. doi: 10.1016/S1470-2045(11)70002-X.

55. Mitchell A.J., Meader N., Davies E. et al. Metaanalysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the depression in cancer care consensus group. J. Affect. Disord. 2012; 140:149–160. doi: 10.1016/j.jad.2011.12.043.

56. Moyniham J.A. Mechanisms of stress-induced modulation of immunity. Brain Behav. Immun. 2003; 17(suppl):11–16.

57. Mulick A., Walker J., Puntis S. et al. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Lancet Psychiatry. 2018; 5(4):321–326. doi: 10.1016/S2215-0366(18)30061-0.

58. Oh P.J., Jang E.S. Effects of psychosocial interventions on cortisol and immune parameters in patients with cancer: A meta analysis. J. Korean Acad. Nurs. 2014; 44(4):446–57. doi: 10.4040/jkan.2014.44.4.446.

59. Oh P.J., Shin S.R., Ahn H.S., Kim H.J. Metaanalysis of psychosocial interventions on survival time in patients with cancer. Psychol. Health. 2016; 31:396–419. doi: 10.1080/08870446.2015.1111370.

60. Okamura M., Yamawaki S., Akechi T. et al. Psychi- atric disorders following first breast cancer recur- rence: prevalence, associated factors and relation- ship to quality of life. Jpn. J. Clin. Oncol. 2005; 35:302-309. doi: 10.1093/jjco/hyi097.

61. Palermo-Neto J., Massoco C.O., Fávare R.C. Effects of maternal stress on anxiety levels, macrophage activity, and Ehrlich tumor growth. Neurotoxicol. Teratol. 2001; 23:497–507.

62. Passik S.D., Dugan W., McDonald M.V. et al. On- cologists’ recognition of depression in their patients with cancer. J. Clin. Oncol. 1998; 16:1594–1600. doi: 10.1200/JCO.1998.16.4.1594.

63. Paykel E.S., Brugha T., Fryers T. Size and burden of depressive disorders in Europe. Eur. Neuropsy- chopharmacol. 2005; 15(4):411-423. doi: 10.1016/j.euroneuro.2005.04.008.

64. Pinquart M., Duberstein P.R. Depression and cancer mortality: a meta-analysis. Psychol. Med. 2010; 40:1797–1810. doi: 10.1017/S0033291709992285.

65. Rasic D.T., Belik S.L., Bolton J.M. et al. Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology. 2008; 17:660–667. doi: 10.1002/pon.1292.

66. Reiche E.M., Nunes S.O., Morimoto H.K. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004; 5(10):617–625. doi: 10.1016/S1470-2045(04)01597-9.

67. Robins L.N., Wing J., Wittchen H.U. et al. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry. 1988; 45:1069– 1077. doi: 10.1001/archpsyc.1988.01800360017003.

68. Robles T.F., Glaser R., Kiecolt-Glaser J.K. Out of Balance: A New Look at Chronic Stress, Depression, and Immunity. Current Directions in Psychol. Sci. 2005; 14(2):111–115. DOI: 10.1111/j.0963-7214.2005.00345.x.

69. Rush S.E., Sharma M. Mindfulness-Based Stress Reduction as a Stress Management Intervention for Cancer Care: A Systematic Review. J. Evid. Based Complementary Altern. Med. 2017; 22(2):348–360. doi: 10.1177/2156587216661467.

70. Sadock B.J., Sadock V.A., Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry (2 Volume Set) Tenth, 2 Volume Set Edition. Lippincott Williams and Wilkins. 2017; 4997p.

71. Sapolsky R.M. Stress hormones: good and bad. Neurobiol. Dis. 2000; 7(5):540–542. doi: 10.1006/nbdi.2000.0350.

72. Serfaty M., King M., Nazareth I. et al. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT. Health Technol. Assess. 2019; 23(19):1–106. doi: 10.3310/hta23190.

73. Serra D., Parris C.R., Carper E. et al. Outcomes of guided imagery in patients receiving radiation therapy for breast cancer. Clin. J. Oncol. Nurs. 2012; 16(6):617–623. doi: 10.1188/12.CJON.617-623.

74. Smith A.B., Rush R., Velikova G. et al. The initial development of an item bank to assess and screen for psychological distress in cancer patients. Psychooncology. 2007; 16:724–732. doi: 10.1002/pon.1117.

75. Smith R. Depression in cancer patients: Patho- genesis, implications and treatment (Review). Oncol. Lett. 2015; 9(4):1509–1514. doi: 10.3892/ol.2015.2944.

76. Sollner W., DeVries A., Steixner E. et al. How suc- cessful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? Br. J. Cancer. 2001; 84:179–185. doi: 10.1054/bjoc.2000.1545.

77. Song QH, Xu RM, Zhang QH, Ma M, Zhao XP. Relaxation training during chemotherapy for breast cancer improves mental health and lessens adverse events. Int. J. Clin. Exp. Med. 2013; 6(10):979–984.

78. Spicer R.S., Miller T.R. Suicide acts in 8 states: Incidence and case fatality rates by demographics and method. Am. J. Public Health. 2000; 90:1885–1891. doi: 10.2105/ajph.90.12.1885.

79. Spiegel D., Bloom J.R., Kraemer H.C., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; 2:888–891. doi: 10.1016/s0140-6736(89)91551-1.

80. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry. 2003; 54:269–282. doi: 10.1016/s0006-3223(03)00566-3.

81. Strong V., Waters R., Hibberd C. et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet. 2008; 372(9632):40–48. doi: 10.1016/S0140-6736(08)60991-5.

82. Trask P.C. Assessment of depression in cancer patients. J. Natl. Cancer Inst. Monogr. 2004; (32):80– 92. doi: 10.1093/jncimonographs/lgh013.

83. Vodermaier A., Linden W., Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J. Natl. Cancer Inst. 2009; 101:1464–1488. doi: 10.1093/jnci/djp336.

84. Walker J., Sharpe M. Depression care for people with cancer: a collaborative care intervention. Gen. Hosp. Psychiatry. 2009; 31(5):436–441. doi: 10.1016/j.genhosppsych.2009.05.010.

85. Watson D. Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSMV. J. Abnorm. Psychol. 2005; 114(4):522–536. doi: 10.1037/0021-843X.114.4.522.

86. Weissman M.M., Neria Y., Gameroff M.J. et al. Positive screens for psychiatric disorders in primary care: a long-term follow-up of patients who were not in treatment. Psychiatr. Serv. 2010; 61:151–159. doi: 10.1176/ps.2010.61.2.151.

87. WHO. In The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Re- search. World Health Organization: Geneva, 1993.

88. Williams S., Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: A systematic review. Br. J. Cancer. 2006; 94:372–390. doi: 10.1038/sj.bjc.6602949.

89. Xia Y., Tong G., Feng R. et al. Psychosocial and behavioral interventions and cancer patient sur- vival again: hints of an adjusted meta-analy- sis. Integr. Cancer Ther. 2014; 13:301–309. doi: 10.1177/1534735414523314.

90. Yousaf U., Christensen M.L., Engholm G., Storm H.H. Suicides among Danish cancer patients 1971–1999. Br. J. Cancer. 2005; 92:995–1000. doi: 10.1038/sj.bjc.6602424.

91. Zabora J., BrintzenhofeSzoc K., Curbow B. et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001; 10(1): 19–28.


Для цитирования:


Блинков А.Н. Депрессия и рак: основные направления международных исследований. Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. 2020;(2):16-25. https://doi.org/10.31363/2313-7053-2020-2-16-25

For citation:


Blinkov A.N. Depression and Cancer (literature review). V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2020;(2):16-25. (In Russ.) https://doi.org/10.31363/2313-7053-2020-2-16-25

Просмотров: 114


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2313-7053 (Print)